Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001127855-12-000521
Filing Date
2012-09-26
Accepted
2012-09-26 13:10:09
Documents
10
Period of Report
2012-02-29

Document Format Files

Seq Description Document Type Size
1 NAPRODIS 10Q, 02.29.12 naprodis10q022812.htm 10-Q 448403
2 NAPRODIS 10Q, CERTIFICATION 302, CEO naprodisexh31_1.htm EX-31.1 11704
3 NAPRODIS 10Q, CERTIFICATION 302, CFO naprodisexh31_2.htm EX-31.2 11183
4 NAPRODIS 10Q, CERTIFICATION 906, CEO/CFO naprodisexh32_1.htm EX-32.1 6541
  Complete submission text file 0001127855-12-000521.txt   1995506

Data Files

Seq Description Document Type Size
5 napr-20120229_cal.xml EX-101.CAL 20182
6 napr-20120229_def.xml EX-101.DEF 41237
7 napr-20120229.xml EX-101.INS 308463
8 napr-20120229_lab.xml EX-101.LAB 73926
9 napr-20120229_pre.xml EX-101.PRE 55325
10 napr-20120229.xsd EX-101.SCH 10885
Mailing Address 13250 GREGG STREET SUITE F POWAY CA 92064
Business Address 13250 GREGG STREET SUITE F POWAY CA 92064 (858) 486-8655
Naprodis, Inc. (Filer) CIK: 0001313938 (see all company filings)

EIN.: 330903494 | State of Incorp.: NV | Fiscal Year End: 0831
Type: 10-Q | Act: 34 | File No.: 333-122009 | Film No.: 121110706
SIC: 2834 Pharmaceutical Preparations